Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
8.26
+0.03 (0.36%)
At close: Mar 23, 2026, 4:00 PM EDT
8.26
0.00 (0.00%)
After-hours: Mar 23, 2026, 4:00 PM EDT
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,220,846
Market Cap
222.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
| Sep 30, 2021 | 6 | - | - |
| Jun 30, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 147 |
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Alector | 103 |
| Editas Medicine | 87 |
| Keros Therapeutics | 78 |
| Cybin | 50 |
| Surrozen | 41 |
NVCT News
- 5 weeks ago - Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - GlobeNewsWire
- 4 months ago - Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC - GlobeNewsWire
- 4 months ago - CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 7 months ago - Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 months ago - Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewsWire
- 8 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire